Partial remission and early stages of pediatric type 1 diabetes display immunoregulatory changes. A pilot study
Villalba Felipe, Adrián (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Fonolleda, Mireia (Institut Germans Trias i Pujol)
Murillo-Vallés, Marta (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Rodríguez-Fernández, Silvia (Institut Germans Trias i Pujol)
Ampudia Carrasco, Rosa María (Institut Germans Trias i Pujol)
Perna-Barrull, David (Institut Germans Trias i Pujol)
Raina, María Belén (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Quirant, Bibiana (Institut Germans Trias i Pujol)
Planas, Raquel (Institut Germans Trias i Pujol)
Teniente Serra, Aina (Institut Germans Trias i Pujol)
Bel, Joan (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Vives Pi, Marta (Institut Germans Trias i Pujol)
Universitat Autònoma de Barcelona

Data:	2019
Resum:	Type 1 diabetes (T1D) is a chronic metabolic disease of unknown etiology that results from β-cell destruction. The onset of the disease, which arises after a long asymptomatic period of autoimmune attack, may be followed by a relapsing and remitting progression, a phenomenon that is most evident during the partial remission phase (PR). This stage lasts for a few months, shows minor requirements of exogenous insulin and could be explained by a recovery of immunological tolerance. This study aims to identify new biomarkers at early stages of pediatric T1D that reflect immunoregulatory changes. To that end, pediatric patients with T1D (n = 52) and age-related control subjects (n = 30) were recruited. Immune response-related molecules and lymphocyte subsets were determined starting at T1D onset and until the second year of progression. Results showed that circulating TGF-β levels decreased during PR, and that betatrophin concentration was increased in all the considered stages without differing among studied checkpoints. Moreover, an increase of regulatory T, B and NK subsets was found during T1D progression, probably reflecting an attempt to restore self-tolerance. By contrast, a reduction in monocyte levels was observed at the early stages of diabetes. The results reveal significant changes in immunological parameters during the different early stages of T1D in children, which could ultimately serve as potential biomarkers to characterize the progression of T1D.
Ajuts:	Instituto de Salud Carlos III PI18-00436
Nota:	Altres ajuts: This work has been funded by the European Regional Development funds (FEDER), and by DiabetesCero Foundation. CIBER of Diabetes and Associated Metabolic Diseases (CIBERDEM) is an initiative from Instituto de Salud Carlos III (Spain). SRF is supported by the Agency for Management of University and Research Grants (AGAUR) of the Generalitat de Catalunya.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Angiopoietin-like Proteins ; Biomarkers ; Body Mass Index ; Case-Control Studies ; Child ; Diabetes Mellitus, Type 1 ; Disease Progression ; Female ; Humans ; Immunologic Memory ; Lymphocyte Subsets ; Male ; Monocytes ; Peptide Hormones ; Pilot Projects ; Remission Induction ; Transforming Growth Factor beta
Publicat a:	Translational Research, Vol. 210 (august 2019) , p. 8-25, ISSN 1878-1810

DOI: 10.1016/j.trsl.2019.03.002
PMID: 30953609

18 p, 2.6 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Articles de recerca
Articles > Articles publicats